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Abstract: Daptomycin is a lipoglycopeptide antibacterial drug that is rapidly bactericidal for 
methicillin-resistant Staphylococcus aureus (MRSA) infection and has antibiotic activity against 
a wide range of Gram-positive organisms. It has been approved by the Ministry of Health, Labor 
and Welfare in Japan for the treatment for bacteremia, right-sided endocarditis, and skin and 
skin-structure infections, such as necrotizing fasciitis, due to MRSA on the basis of a Phase III 
trial conducted in Japan since July, 2011. In Japanese Phase I and III trials, daptomycin therapy 
given at 4 mg/kg and 6 mg/kg once per day was well tolerated and effective as standard therapy for 
the treatment of acute bacterial skin and skin-structure infections and bacteremia caused by 
MRSA, but side effects remain to be evaluated in large-scale trials.
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The problem of MRSA in Japan
Methicillin-resistant Staphylococcus aureus (MRSA) has spread among hospital 
isolates since the 1960s and these strains eventually disseminated worldwide. MRSA 
has long been recognized as one of the major human pathogens responsible for some 
afflictions such as skin and wound infections, bacteremia and endocarditis, infections 
of the central nervous system, respiratory and urinary tracts, and infections associated 
with intravascular devices and foreign bodies, and shown high mortality and mor-
bidity.1 In Japan, MRSA primarily causes nosocomial infections. Four hundred and 
eighty-seven hospitals participated in the Japan Nosocomial Infection Surveillance 
(JANIS)   system performed by the Japanese Ministry of Health, Labor and Welfare. 
The recorded MRSA prevalence among S. aureus isolates was 57.6% (100845/175145 
strains) in 2010.2 This result was similar to the results from the National Nosocomial 
Infections Surveillance (NNIS) in the USA (52.9% in intensive care units [ICU]; 
46.0% in non-ICU wards).3
The recent emergence of decreased susceptibility to vancomycin, as the standard 
treatment for invasive MRSA infection due to its low cost and extensive experience 
with MRSA phenotypes, such as vancomycin minimum inhibitory concentrations 
(MICs) of 2 µg/mL, heterogeneous vancomycin-intermediate S. aureus (hVISA), and 
vancomycin-intermediate S. aureus (VISA), presents a significant correlation with the 
mortality of patients infected with these isolates.4–6 Takesue et al compared several 
characteristics of 128 episodes of Japanese MRSA bacteremia between 2005 and 2008 
with 631 other MRSA infections. Consequently, the clinical efficacy as first-line therapy 
in patients infected with 2 µg/mL strains was significantly lower than that for patients 
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infected with #1 µg/mL strains (30.0% vs 78.8%; P , 0.001) 
in bacteremia; mortality was significantly higher in patients 
with 2 µg/mL strains than in patients with #1 µg/mL strains 
(65.8% vs 19.5%; P , 0.001).7
While some in vitro studies had already suggested that 
combination therapies of glycopeptides and β-lactams show 
synergistic effects for MRSA phenotypes and decreased 
vancomycin susceptibility,8 Hatano et al proposed that the 
existence of MRSA strains showing antagonistic effects for 
the combination therapy should be called β-lactam antibiotic-
induced vancomycin-resistant MRSA (BIVR).9 In the epide-
miological investigation including two university hospitals, 
one hospital with 800 beds, and four hospitals with 300–500 
beds in Japan,10 the BIVR detection rate was 6.7% (45 in 
717 clinical MRSA isolates). Likewise, 11 linezolid (LZD)-
resistant clinically isolated MRSA with MICs of .4 µg/mL 
from 11 patients at six hospitals in Japan were collected from 
2006 through 2008. Alternative vancomycin-resistant strains 
have also been reported in Japan, while their incidences in 
clinical isolates are still as low as in the USA.11,12
Moreover, MRSA infections are no longer confined 
to health care institutions. MRSA strains isolated from 
community-acquired infections are becoming increas-
ingly common. Recent research suggests that the virulence 
of   community-acquired MRSA (CA-MRSA) infection is 
at least partially due to overexpression of toxins, such as 
Panton-Valentine leucocidin (PVL), α-toxin, and toxic shock 
syndrome toxin (TSST-1)13,14 and subsequent host inflamma-
tory response.15 In Japan, CA-MRSAs such as pulsed-field 
type USA300 MRSA strain infections producing PVL have 
also been reported since 1970–1980,16 while the detection rate 
of CA-MRSA strains remains less than in the USA.17
Overview of the current options  
for the treatment of MRSA
Increasing vancomycin-resistant MRSA strains in con-
junction with availability of new antibiotics, including 
daptomycin, have increased treatment choices but made 
clinical treatment decisions more challenging. Nowadays, 
alternative options for the treatment of MRSA infections in 
Japan are: the glycopeptides, teicoplanin; the oxazolidinone, 
LZD; the cyclic lipopeptide, daptomycin; and the amino-
glycoside, arbekacin. Other agents with potential activity 
against MRSA are quinupristin–dalfopristin, trimethoprim– 
sulfamethoxazole, clindamycin, erythromycin, tetracycline, 
rifampicin, and the fluoroquinolones. However, the use of 
these latter agents is generally restricted to cases of noninva-
sive S. aureus infections or is avoided because of widespread 
resistance, and they cannot be recommended for the treatment 
of invasive disease.
Although vancomycin is almost universally accepted as 
the drug of choice for the treatment of most MRSA infec-
tions, some shortcomings have been recognized, such as 
being less rapidly bactericidal compared with β-lactams 
against S. aureus, especially at higher inoculums,18 poor 
tissue and intracellular penetration, lack of activity against 
organisms growing in biofilm, and lack of interference 
with toxin   production. The recent emergence of decreased 
  vancomycin susceptibility in S. aureus, including isolates 
with   vancomycin mininum inhibitory concentrations (MICs), 
presents a significant clinical problem.
Teicoplanin shows a spectrum of activity similar to 
that of vancomycin, to which it is closely related, and also 
has a mechanism of action similar to that of vancomycin. 
  Compared with vancomycin, teicoplanin has a relatively long 
half-life and better tissue penetration due to its high protein-
binding potency.19 Clinical data reported that an early loading 
dose of teicoplanin achieves a good therapeutic effect.20,21 
Comparative meta-analysis of the clinical effects of teicopla-
nin and vancomycin included 24 studies (2610 patients) and 
suggested that, while both antibiotics achieved the equivalent 
clinical cure (risk ratio [RR]. 1.03; 95% confidence interval 
[CI]: 0.98–1.08) and microbiological cure (RR, 0.98; 95% 
CI: 0.93–1.03), teicoplanin has less nephrotoxic potential 
than vancomycin (RR, 0.51; 95% CI: 0.30–0.88).22
Linezolid has good tissue migration, does not need dosage 
titration for kidney function and therapeutic drug monitoring, 
and can be switched from intravenous to oral due to having 
preparation and oral forms. The major adverse event asso-
ciated with LZD treatment is reversible myelosuppression, 
mostly thrombocytopenia. The incidence of LZD-induced 
thrombocytopenia was higher in patients with renal failure 
than in patients with normal renal function, although the 
underlying mechanisms of this toxicity are still unknown.23 
A meta-analysis including nine relevant randomized, con-
trolled trials studied 2489 clinically assessed patients and 
found that LZD showed higher clinical effect for skin and soft 
tissue infection (odds ratio [OR], 1.40; 95% CI: 1.01–1.95), 
while it showed equivalent therapeutic effect with 
  vancomycin for bacteremia (OR, 0.88; 95% CI: 0.49–1.58), 
pneumonia (OR, 1.16; 95% CI: 0.85–1.57) patients.24 In con-
trast, there was no difference in total adverse effects (OR, 
1.14; 95% CI: 0.82–1.59).
Arbekacin excels in bactericidal activity against MRSA 
as well as daptomycin, and also has antibacterial activity 
for Pseudomonas aeruginosa. For more than 10 years in 
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Japan, arbekacin has been successfully used to treat MRSA 
infections. However, due to its poor penetration and adverse 
effects such as nephrotoxicity and ototoxicity, arbekacin is 
rarely used as first-line therapy for MRSA infections.25
Daptomycin is a new lipoglycopeptide antibacterial drug 
that is rapidly bacterial for MRSA infection. It was approved 
for the treatment for bacteremia, right-sided endocarditis, and 
skin and skin-structure infections such as necrotizing fasciitis 
due to MRSA on the basis of a Phase III trial conducted in 
Japan that revealed that daptomycin therapy was noninfe-
rior to vancomycin therapy for this indication. In the early 
studies of daptomycin use in dogs, skeletal muscle toxicity 
was observed frequently, as measured by elevations of the 
creatinine phosphokinase (CPK) muscle isoenzyme, and the 
experiments revealed that once-daily dosing is much less 
frequently associated with this adverse effect.26
Pharmacology of daptomycin
Mode of action
The antibacterial activity of daptomycin is believed to 
be mediated through depolarization of the bacterial cell 
  membrane. The hydrophobic tail of the daptomycin molecule 
is inserted into and irreversibly binds within the bacterial cell 
membrane in a calcium-dependent process.27 Subsequent 
oligomerization of the molecules within the membrane 
leads to the formation of pores or ion channels, which 
allow potassium efflux from the bacterial cytoplasm, thus 
destroying the ion concentration gradient;28 this depolarizes 
the cell membrane and causes rapid cell death through the 
inhibition of DNA, RNA, and protein synthesis.   Additionally, 
a recent study suggests that potassium leakage is not the only 
mechanism: magnesium and adenosine triphosphate loss 
may also play a role.29
Antibacterial spectrum
Daptomycin is active against Gram-positive bacteria. Its 
spectrum includes staphylococci, streptococci including 
Streptococcus pneumoniae, and enterococci (including 
vancomycin-resistant strains).30 It is also active against 
some anaerobic organisms, such as peptostreptococci and 
clostridia, including Clostridium difficile.31 However, dapto-
mycin shows no activity against Gram-negative bacteria.
Resistance
Although the mechanism of resistance is not clear, single 
mutations in mpr F or yyCG, the lysylphosphatidylglycerol 
synthetase gene, are often presented in such strains.32,33 Julian 
et al revealed the change of the muropeptide profile with 
these strains. The daptomycin-nonsusceptible VISA’s cell 
wall demonstrated a reduction in muramic acid O-acetylation, 
a phenotypic parameter not previously reported for VISA.33 
Moreover, Muthaiyan et al suggested that the expression 
profile indicated that cell wall stress stimulon member 
genes were significantly induced by daptomycin and by the 
cell wall-active antibiotics vancomycin and oxacillin. They 
compared the daptomycin response of a two-component cell 
wall stress stimulon regulator VraSR mutant, S. aureus KVR, 
to its parent N315 and found diminished expression of the 
cell wall stress stimulon in the mutant.34
Prior exposures to vancomycin and elevated vancomycin 
MICs have been associated with increases in daptomycin 
MICs, suggesting possible cross-resistance.35–37 The popula-
tion analysis of some MRSA phenotypes with vancomycin 
MIC 1–8 µg/mL in blood from infected patients revealed that 
treatment with vancomycin was associated with the devel-
opment of vancomycin heterogeneous resistance and was 
accompanied by daptomycin heteroresistance.36 In MRSA, 
including VISA, physiologic changes or cell wall changes 
may interfere with daptomycin activity by decreasing the 
ability of daptomycin, a relatively large molecule, to access 
relevant binding regions on the bacterial cell membrane.
Pharmacokinetic properties
In Japan, the approved dose of daptomycin is 4–6 mg/kg 
every 24 hours. In the Japanese Phase I trial, healthy subjects 
(n = 6) received single doses of 2 to 12 mg/kg of daptomycin 
by 30-minute intravenous infusion. Daptomycin showed 
liner pharmacokinetics with a half-life of 7.4–10.2 hours and 
73.4% was excreted in the urine in an unmetabolized form. 
One week after daptomycin dosing of 4, 6 and 10 mg/kg every 
24 hours, 24-hour area under the curve (AUC0–24) values at 
steady state from healthy volunteers were 424.7 µg*hour/mL 
(95% CI: 392.5–459.5), 601.4 µg*hour/mL (95% CI: 555.8–
650.7), and 1094.6 µg*hour/mL (95% CI: 1011.6–1184.4), 
respectively. The volume of distribution at steady state in 
healthy subjects was low (0.1 L/kg), indicating that it remains 
primarily in plasma and interstitial fluid. Although protein 
binding to plasma protein was high (90%–93%), it decreased 
in patients with a creatinine clearance of ,30 mL/minute 
and was reversible, therefore protein-bound daptomycin is 
bioavailable and is independent of the drug concentration. 
However, the percentage of free drug is not a good predictor 
of biological effect for daptomycin.38
Furthermore, as daptomycin does not interact with the 
P450 cytochromes, there are no interactions with other 
drugs via this mechanism.39 Daptomycin is inactivated by 
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surfactant in the lung and is not indicated for the treatment 
of pneumonia,40,41 and is not to be used to treat pneumonia 
and left-sided endocarditis.
Pharmacodynamics of daptomycin
Japanese clinical Phase III trial
Study design
The Japanese clinical Phase III trial was conducted as a 
randomized, open-label, active-comparator, parallel-group, 
multicenter study at 61 institutions from 2008 through 
2010.42,43 Eligible patients were aged over 20 years. Primary 
inclusion criteria were bacteremia with or without right-sided 
endocarditis and acute bacterial skin and skin-structure infec-
tions (ABSSSI), including wound infections (eg, surgical 
and traumatic wounds), major abscesses, infected diabetic 
ulcers of extremity, and infected ulcers due to other causes 
(eg, ulcers associated with vascular insufficiency or decubiti) 
that were due to MRSA and required hospitalization. Patients 
with ABSSSI were randomized 4:1 to receive intravenous 
daptomycin (4 mg/kg) once-daily or vancomycin (1 g) twice 
daily for 7–14 days. There was no comparative arm set for 
bacteremia with or without right-side endocarditis, and thus 
all patients received intravenous daptomycin 6 mg/kg once 
daily over 30 minutes for 14–42 days.
Outcomes were based primarily on clinical and microbio-
logic assessments, compared with baseline (within 48 hours 
before receipt of the first dose of study drug). Clinical assess-
ments of signs and symptoms were recorded and assessed for 
potential adverse events during study therapy. Efficacy was 
assessed at the end of therapy and at 7–14 days (in ABSSSI 
patients) or 38–46 days (in bacteremia with or without 
right-side endocarditis) of the last dose of study medication 
for test-of-cure. The coprimary efficacy endpoints were 
the clinical and microbiologic response at test-of-cure. All 
assessments were reassessed by the Efficacy Adjudication 
Committee. Successful clinical response was defined as the 
clinical assessment of “cure” or “improved” at both the end of 
therapy and test-of-cure; not receiving a nonstudy antibacte-
rial agent with potency against causative pathogen; receiving 
study drugs for at least 4 (ABSSSI group) or 7 (bacteremia 
with or without right-side endocarditis group) days; and 
a negative blood culture at test-of-cure for the causative 
pathogen (bacteremia with or without right-side endocarditis 
group). A successful microbiologic response was defined as 
eradication or presumed eradication of the pathogen.
For the safety analysis, the adverse events and con-
comitant medications were monitored daily. Vital signs and 
clinical laboratory parameters, including clinical chemistry, 
hematology, and urinalysis findings, were assessed at each 
scheduled evaluation.
Susceptibility
Across the Phase III trial, 121 patients were enrolled and 
received $1 dose of study medication; these patients 
constituted 110 ABSSSI patients and 11 bacteremia with or 
without right-side endocarditis patients. MICs of baseline 
78 isolates from patients who participated in the Phase 
III clinical trial against anti-MRSA agents were measured 
by broth microdilution method according to the Clinical 
and Laboratory Standards Institute testing guidelines.44 
The MIC50 and MIC90 values against MRSA strains were 
isolated for daptomycin, vancomycin, teicoplanin, arbekacin, 
and LZD and were 0.5/0.5 (range, 0.25–1 µg/mL), 1/1 
(0.5–2 µg/mL), 1/4 (0.25–8 µg/mL), 1/2 (0.25–4 µg/mL), 
2/2 (1–4 µg/mL)µg/mL, respectively. Daptomycin exerted the 
highest antibacterial activity; the number of resistant strains 
was 0% (susceptibility: #1 µg/mL). Additionally, while not 
Phase III data, MRSA MICs results (100 isolates derived 
from blood and 200 isolates derived from skin-related tissues) 
isolated in Japan showed almost the same MIC50 and MIC90 
results as the Phase III study; daptomycin MIC90 was 1 µg/mL 
(range 0.25–1 µg/mL), regardless of the isolated parts. Hence, 
the distribution of daptomycin MIC values among Japanese 
MRSA was not wide (0.25–1 µg/mL) and it showed good 
susceptibility against MRSA isolated in Japan.
Efficacy for ABSSSI
In the Phase III trial, 73 and 74 patients of 110 ABSSSI 
patients were eligible for efficacy (end-of-cure and test-of-
cure) analysis. Among 73 evaluated patients, the clinical 
efficacy (end-of-cure) of daptomycin was 85.2% (46 of 
54 patients), compared with 84.2% (16 of 19 patients) for 
the vancomycin group. In the microbiological efficacy 
analysis, 24 of 55 patients (43.6%) who received dapto-
mycin showed efficacy and 9 of 19 patients (47.4%) who 
received vancomycin showed efficacy. Additionally, among 
74 evaluated patients, the clinical efficacy (test-of-cure) 
of daptomycin was 81.8% (45 of 55 patients) compared 
with 84.2% (16 of 19 patients) for the vancomycin group. 
In the microbiological efficacy analysis, 31 of 55 patients 
(56.4%) who received daptomycin showed efficacy and 9 
of 19 patients (47.4%) who received vancomycin showed 
efficacy. Especially in the patients with MRSA infections 
from trauma, burn and post-surgical skin and soft tissue 
infections, daptomycin and vancomycin had 81.6% (31 
of 38 patients) and 84.6% (11 of 13 patients) clinical 
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efficacy, respectively. On the other hand, for the patients 
with infected ulcers and ulceration, daptomycin and 
  vancomycin showed 100% (9 of 9 patients) and 80% (4 of 
5 patients) clinical efficacy, respectively.
Efficacy for bacteremia
Among 11 bacteremia patients, four patients were eligible for 
efficacy analysis. There were no endocarditis patients. Among 
four patients, end-of-cure clinical and microbiological suc-
cess rates were 50% (2/4 patients) and 100% (4/4 patients), 
respectively. Test-of-cure clinical and microbiological 
success rates were both 50% (2/4 patients). Compared with 
another clinical study, while the number of patients was low 
in the Japanese Phase III trial, daptomycin showed similar 
efficacy with non-Japanese bacteremia patients infected 
with MRSA.45
Therefore, this Phase III clinical trial demonstrated that 
daptomycin is as effective as standard therapy for the treat-
ment of ABSSSI, and daptomycin was also effective in the 
treatment of bacteremia associated with MRSA infections 
in Japanese as well as non-Japanese patients.45,46
Safety and tolerability
Across the studies, 99 and 22 patients who received dap-
tomycin and vancomycin, respectively, were enrolled in 
safety analysis. During the Phase III trial, daptomycin 
was generally well tolerated; 23 of 99 daptomycin-treated 
patients (23.2%) experienced adverse events considered 
to be related to study treatment; the major adverse events 
were composed of elevation of aspartate aminotransferase 
(seven patients, 7.1%), alanine aminotransferase (seven 
patients, 7.1%), alkaline phosphatase (two patients, 2.0%), 
CPK (two patients, 2.0%), eosinophil (two patients, 2.0%) 
levels, eczema (two patients, 2.0%), fever (two patients, 
2.0%), diarrhea (two patients, 2.0%), and decreasing platelet 
level (two patients, 2.0%). The frequency and distribution of 
adverse effects were similar in both treatment groups; six of 
22 patients (27.3%) of comparator agent treated experienced 
adverse effects. While in the early trials of daptomycin 
use, skeletal muscle toxicity was observed frequently, as 
measured by elevations of the CPK muscle isoenzyme, in 
the Japanese Phase III trial, no patient experienced severe 
elevation of CPK. Treatment discontinuations due to adverse 
effects related to treatment drugs occurred for three patients 
(3%) in the daptomycin group and two patients (9.1%) in 
the comparator group. Two patients in each treatment group 
died during the study; none of the deaths were considered 
to be treatment-related.
Non-Japanese studies
As daptomycin has been approved for use in Japan for 
less than one year, there is limited clinical, in vivo, and in 
vitro data to support using the drug. However, daptomy-
cin has been investigated in other countries. Safdar et al 
showed that AUC0–24/MIC and maximum concentration/
MIC showed best correlation with antibacterial activity 
with an in vivo study and daptomycin also had a long last-
ing postantibiotic effect (PAE) of 5 hours activity against   
S. aureus, including MRSA and VISA, with daptomycin 
MIC 0.125 to 4 µg/mL using an in vitro pharmacodynamic 
model simulating human exposure (0 to 9 mg/kg). Conse-
quently, model fitting resulted in an r2 of .0.80 for all iso-
lates showing significant bactericidal activity (ED80) against 
these isolates with daptomycin dose ranging between 3 and 
7 mg/kg. Additionally, daptomycin has been demonstrated 
to have a rapid bactericidal effect against organisms with 
elevated daptomycin MICs, including VISA.48
The addition of rifampicin to daptomycin also enhanced 
bacterial killing in an animal study with MRSA experimental 
aortic valve endocarditis.49 The activity of the combination 
therapies and dual combination was evaluated in rats with 
MRSA experimental aortic valve endocarditis. 49 As a result, 
the combination of daptomycin and rifampicin produced a 
lower remaining bacterial vegetation density at the end of 
therapy than daptomycin alone (2.9 ± 0.8 vs 4.6 ± 1.6 log10 
cfu/g vegetation; P = 0.006). Daptomycin was also evalu-
ated alone and in combination with rifampicin in a guinea 
pig foreign-body MRSA infection model.50 After 4 days of 
treatment, daptomycin monotherapy eradicated the infection 
in 4/12 (33%) animals, with daptomycin and rifampicin 
resulting in a 67% cure rate. Likewise, daptomycin sub-MICs 
combined with gentamicin concentrations lower than the MIC 
yielded synergy in 34 (68%) of the 50 S. aureus strains, as 
well as between daptomycin and various β-lactams against 
MRSA.46 Animal studies models of S. aureus endocarditis 
vegetations suggested that adding gentamicin to daptomycin 
dosed at either 6 or 10 mg/kg/day potentiated bactericidal 
activity, generally more so than rifampicin.49,51 While there are 
no published randomized clinical trials comparing the com-
bination of daptomycin alone to daptomycin–  aminoglycoside 
in patients with serious MRSA infections, vancomycin–
gentamicin was numerically inferior to daptomycin alone 
in the treatment of MRSA bacteremia and endocarditis in 
a randomized trial, although statistical significance was 
not achieved (14 [31.8] of 44 vs 20 [44.4%] of 45 patients; 
P = 0.28).45,52
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Additionally, daptomycin is active in the static and growth 
phases of bacteria,46,53 a property that is highly unusual. 
While biofilm formation is an important virulence factor 
that allows bacteria to resist host responses and antibacterial 
agents, in vitro activities of several antibiotics against two   
S. aureus with pharmacokinetic–pharmacodynamic model, 
the combination of daptomycin and rifampicin was also bac-
tericidal against biofilm-produced MRSA isolates, achieving 
the limit of detection at 72 hours.
Patient-focused perspectives  
such as patient satisfaction  
and acceptability
One of the major drawbacks of daptomycin is its lack of 
effectiveness to treat pulmonary infections since surfactants 
render it ineffective. Silverman et al found that the interac-
tion of daptomycin with pulmonary surfactant41 in an animal 
pneumonia model exhibited an unusual pattern of activity, 
although daptomycin has failed to meet statistical noninferi-
ority criteria in a clinical trial for severe community-acquired 
pneumonia, compared to ceftriaxone.40
Hanberger et al evaluated the influence of Ca2+ and 
albumin on daptomycin with S. aureus in an in vitro study. 
  Consequently, although the MICs of daptomycin was not 
influenced by different Ca2+ concentrations, MICs for 
S. aureus were lowered and PAE were prolonged with increas-
ing concentrations of Ca2+ in the broth. Herein,   daptomycin 
antibacterial activity could be important to ascertain a 
  physiologic free Ca2+ concentration.54
Compared with healthy volunteers, clearance in subjects 
on dialysis is approximately one-third of that in nondialysis 
subjects (0.27 vs 0.81 L/hour).55 While there is no dose 
adjustment recommended for patients with renal impair-
ment and creatinine clearance .30 mL/minute, in patients 
with ,30 mL/minute, the dose recommendation is 4 mg/kg 
every 48 hours in patients on hemodialysis or continuous 
ambulatory peritoneal dialysis, dose administration is rec-
ommended postdialysis on dialysis days.56 Additionally, 
in patients with mild-to-moderate hepatic impairment, the 
pharmacokinetics of daptomycin are not significantly altered 
and no dosage adjustment is necessary.
Moreover, some studies suggested that treatment with 
vancomycin was associated with the development of van-
comycin heterogeneous resistance and accompanied by dap-
tomycin heteroresistance.36 Hence, patients heavily exposed 
to vancomycin prior to treatment with daptomycin may be 
at increased risk of a suboptimal response to daptomycin if 
a nonsusceptible subpopulation emerges.
As the results of early trials of daptomycin revealed, 
patients should be observed for development of muscle 
pain or weakness and have weekly CPK levels determined, 
which may require more frequent monitoring in those with 
renal insufficiency or who are receiving concomitant statin 
therapy. However, elevations in CPK are rarely treatment-
limiting. In a prospective trial conducted in foreign country 
comparing daptomycin with conventional treatment for 
bacteremia and endocarditis, CPK elevations occurred in 
6.7% of patients in the daptomycin arm compared with 
0.9% in patients in the standard therapy group;45 in most 
patients, CPK levels returned to normal during treatment. 
Additionally, there have been case reports of rhabdomy-
olysis during daptomycin use; it has also been observed 
in patients on concomitant treatment with 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase inhibi-
tors.57 Additionally, daptomycin has been shown to interact 
with thromboplastin reagents and cause a falsely elevated 
International Normalized Ratio.58
Furthermore, several case reports of daptomycin that 
include eosinophilic pneumonia have been described although 
the mechanisms was not known.59 The   pharmacokinetics, 
safety, and efficacy of daptomycin in children have not been 
established. Daptomycin is coded category B for   pregnancy. 
Lastly, daptomycin is not compatible with dextrose-  containing 
diluents due to incompatibilities.
Conclusions
Increasing treatment choices for MRSA infection, vancomy-
cin’s shortcomings, and the emergence of new MRSA strains 
with lower susceptibility against vancomycin are changing 
perceptions. The Japanese Phase III clinical trial data of 
daptomycin show that the highest susceptibility compared 
with other anti-MRSA agents and the efficacy and safety of 
daptomycin are similar to those of vancomycin for the treat-
ment of ABSSSI and were similar in other clinical studies 
conducted in foreign countries.46 These data suggest that 
daptomycin has been evaluated with promising results in 
MRSA bacteremia and ABSSSI.
Daptomycin has a rapid bactericidal activity associated 
with its unique mechanism of action on the cell membrane. 
Hence, it might result in more rapid clinical resolution 
of infections. Additionally, some clinical studies showed 
that combination therapies were effective for endocardi-
tis and utility in orthopedic infections deserves early 
investigation, as a combination of cidality and activity 
against biofilms suggests potential.47–50 Furthermore, while 
daptomycin has favorable pharmacokinetic properties 
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allowing once-daily dosing and toxicity is rare with the 
currently recommended dosing, some in vitro studies 
suggest daptomycin has the potential for cross-resistance 
with vancomycin.36,37
In summary, daptomycin is the first available agent from 
a new class of antibiotics, the cyclic lipopeptides. It has 
antibiotic activity against a wide range of Gram-positive 
organisms. Especially for MRSA, daptomycin showed 
higher activity than other anti-MRSA agents. The Japanese 
Phase III clinical trial demonstrated that daptomycin given 
at 4 mg/kg and 6 mg/kg once per day is a safe and effective 
standard therapy for the treatment of ABSSSI and bacteremia 
caused by MRSA, but side effects remain to be evaluated in 
large-scale trials.
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